Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer Meeting Abstract

  


Authors: Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Ku, G. Y.; Ilson, D. H.; Hechtman, J. F.; Merghoub, T.; Solit, D. B.; Schultz, N.; Janjigian, Y. Y.
Abstract Title: Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
Meeting Title: 2021 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 39
Issue: 15 Suppl.
Meeting Dates: 2021 Jun 4-8
Meeting Location: Virtual
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2021-05-20
Language: English
ACCESSION: WOS:000708120602159
DOI: 10.1200/JCO.2021.39.15_suppl.4058
PROVIDER: wos
Notes: Meeting Abstract: 4058 -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Marc Z Simmons
    10 Simmons
  2. Taha Merghoub
    365 Merghoub
  3. David Solit
    781 Solit
  4. Geoffrey Yuyat Ku
    233 Ku
  5. Yelena Yuriy Janjigian
    400 Janjigian
  6. Kinh Gian Do
    258 Do
  7. Neeta Pandit-Taskar
    344 Pandit-Taskar
  8. David H Ilson
    436 Ilson
  9. Nikolaus D Schultz
    491 Schultz
  10. Lilan Ling
    44 Ling
  11. Jaclyn Frances Hechtman
    212 Hechtman
  12. Ryan Nathan Ptashkin
    86 Ptashkin
  13. Walid Khaled Chatila
    104 Chatila
  14. Viktoriya Paroder
    60 Paroder
  15. Steven Maron
    106 Maron
  16. Henry Stuart Walch
    100 Walch
  17. Shalom Aima Sabwa
    11 Sabwa
Related MSK Work